Cornea: Window to ocular immunology

Current Immunology Reviews

Volumn 7, Issue 3, 2011, Pages 328-335

  Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Allograft; Cornea; Dry eye; Herpes simplex virus; Immune privilege; T regulatory cells

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 10; MIGRATION INHIBITION FACTOR; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AUTOIMMUNE DISEASE; BLINDNESS; BLOOD VESSEL; CORNEA; CORNEA TRANSPLANTATION; DELAYED HYPERSENSITIVITY; DRY EYE; GRAFT SURVIVAL; HERPES SIMPLEX KERATITIS; HUMAN; IMMUNE MEDIATED INJURY; IMMUNITY; IMMUNOLOGY; IN VIVO STUDY; INFLAMMATION; KERATITIS; LYMPH VESSEL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS KERATITIS; REVIEW;

EID: 79959972186     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/157339511796196593     Document Type: Review

References (108)

1. Miller D. Ophthalmology. The essentials. Boston, Houghton Mifflin Professional Publishers, 1979.
2. Chen WL, Lin CT, Li JW, Hu FR, Chen CC. Erk1/2 activation regulates the wound healing process of rabbit corneal endothelial cells. Curr Eye Res 2009; 34: 103-11.
3. Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res 2003; 22: 359-89.
4. Zeiss CJ, Johnson EM, Dubielzig RR. Feline intraocular tumors may arise from transformation of lens epithelium. Vet Pathol 2003; 40: 355-62.
5. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002; 22: 13-46.
6. Niederkorn JY. See no evil, hear no evil, do no evil: The lessons of immune privilege. Nat Immunol 2006; 7: 354-9.
7. Niederkorn JY, Wang S. Immune privilege of the eye and fetus: Parallel universes? Transplantation 2005; 80: 1139-44.
8. Streilein JW. Ocular immune privilege: Therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003; 3: 879-89.
9. Niederkorn JY. The immune privilege of corneal allografts. Transplantation 1999; 67: 1503-8.
10. Niederkorn JY. The immunology of corneal transplantation. Dev Ophthalmol 1999; 30: 129-40.
11. Niederkorn JY. The immune privilege of corneal grafts. J Leukoc Biol 2003; 74: 167-71.
12. Waldock A, Cook SD. Corneal transplantation: How successful are we? Br J Ophthalmol 2000; 84: 813-5.
13. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice--evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992; 54: 694-704.
14. Niederkorn JY. Mechanisms of corneal graft rejection: The sixth annual thygeson lecture, presented at the ocular microbiology and immunology group meeting, october 21, 2000. Cornea 2001; 20: 675-9.
15. Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Intern Rev Immunol 2002; 21: 173-96.
16. He YG, Ross J, Callanan D, Niederkorn JY. Acceptance of h-ydisparate corneal grafts despite concomitant immunization of the recipient. Transplantation 1991; 51: 1258-62.
17. Peeler JS, Callanan DG, Luckenbach MW, Niederkorn JY. Presentation of the h-y antigen on langerhans' cell-negative corneal grafts downregulates the cytotoxic t cell response and converts responder strain mice into phenotypic nonresponders. J Exp Med 1988; 168: 1749-66.
18. Ross J, He YG, Pidherney M, Mellon J, Niederkorn JY. The differential effects of donor versus host langerhans cells in the rejection of mhc-matched corneal allografts. Transplantation 1991; 52: 857-61.
19. Group CCTSR. The collaborative corneal transplantation studies (ccts). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992; 110: 1392-1403.
20. Hopkins KA, Maguire MG, Fink NE, Bias WB. Reproducibility of hla-a, b, and dr typing using peripheral blood samples: Results of retyping in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies group (corrected). Hum Immunol 1992; 33: 122-8.
21. Reinhard T, Bohringer D, Enczmann J, et al. Improvement of graft prognosis in penetrating normal-risk keratoplasty by hla class i and ii matching. Eye (Lond) 2004; 18: 269-277.
22. Vail A, Gore SM, Bradley BA, et al. Conclusions of the corneal transplant follow up study. Collaborating surgeons. Br J Ophthalmol 1997; 81: 631-6.
23. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10: 813-5.
24. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 2002; 21: 405-9.
25. Cursiefen C, Chen L, Borges LP, et al. Vegf-a stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040-50.
26. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
27. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular vegf receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006; 103: 11405-10.
28. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15: 1023-30.
29. Callanan D, Peeler J, Niederkorn JY. Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation 1988; 45: 437-43.
30. He YG, Niederkorn JY. Depletion of donor-derived langerhans cells promotes corneal allograft survival. Cornea 1996; 15: 82-9.
31. Niederkorn JY, Ross JR, He Y. Effect of donor langerhans cells on corneal graft rejection. J Invest Dermatol 1992; 99: 104S-6S.
32. Niederkorn JY. The induction of anterior chamber-associated immune deviation. Chem Immunol Allergy 2007; 92: 27-35.
33. Streilein JW, Takeuchi M, Taylor AW. Immune privilege, t-cell tolerance, and tissue-restricted autoimmunity. Hum Immunol 1997; 52: 138-43.
34. Niederkorn JY. Anterior chamber-associated immune deviation and its impact on corneal allograft survival. Current Opinion in Organ Transplantation 2006; 11: 360-5.
35. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol 2007; 92: 71-85.
36. Sonoda Y, Streilein JW. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol 1993; 150: 1727-34.
37. Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996; 37: 2700-7.
38. Plskova J, Duncan L, Holan V, et al. The immune response to corneal allograft requires a site-specific draining lymph node. Transplantation 2002; 73: 210-5.
39. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci 2001; 42: 1293-8.
40. Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact cd1d- reactive nkt cells. J Immunol 2002; 168: 2028-34.
41. Gill HK, Liew FY. Regulation of delayed-type hypersensitivity. Iii. Effect of cyclophosphamide on the suppressor cells for delayedtype hypersensitivity to sheep erythrocytes in mice. Eur J Immunol 1978; 8: 172-6.
42. Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H. Cyclophosphamide-sensitive t lymphocytes suppress the in vivo generation of antigen-specific cytotoxic t lymphocytes. J Exp Med 1977; 145: 455-9.
43. She SC, Moticka EJ. Ability of intracamerally inoculated b- and tcell enriched allogeneic lymphocytes to enhance corneal allograft survival. Int Ophthalmol 1993; 17: 1-7.
44. She SC, Steahly LP, Moticka EJ. Intracameral injection of allogeneic lymphocytes enhances corneal graft survival. Invest Ophthalmol Vis Sci 1990; 31: 1950-6.
45. Ferguson TA, Griffith TS. The role of fas ligand and tnf-related apoptosis-inducing ligand (trail) in the ocular immune response. Chem Immunol Allergy 2007; 92: 140-54.
46. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
47. Stuart PM, Griffith TS, Usui N, et al. Cd95 ligand (fasl)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
48. Yamagami S, Kawashima H, Tsuru T, et al. Role of fas-fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997; 64: 1107-11.
49. Lee HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA. Trail: A mechanism of tumor surveillance in an immune privileged site. J Immunol 2002; 169: 4739-44.
50. Wang S, Boonman ZF, Li HC, et al. Role of trail and ifn-gamma in cd4+ t cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol 2003; 171: 2789-96.
51. Hori J, Wang M, Miyashita M, et al. B7-h1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006; 177: 5928-35.
52. Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol 2007; 179: 3672-9.
53. Yang W, Li H, Chen PW, et al. Pd-l1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009; 50: 273-80.
54. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res 2007; 32: 1005-16.
55. Hegde S, Mellon JK, Hargrave SL, Niederkorn JY. Effect of alloantibodies on corneal allograft survival. Invest Ophthalmol Vis Sci 2002; 43: 1012-8.
56. Holan V, Vitova A, Krulova M, et al. Susceptibility of corneal allografts and xenografts to antibody-mediated rejection. Immunol Lett 2005; 100: 211-3.
57. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993; 34: 3579-84.
58. Lass JH, Walter EI, Burris TE, et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990; 31: 1136-48.
59. Goslings WR, Prodeus AP, Streilein JW, et al. A small molecular weight factor in aqueous humor acts on c1q to prevent antibodydependent complement activation. Invest Ophthalmol Vis Sci 1998; 39: 989-95.
60. Hargrave SL, Mayhew E, Hegde S, Niederkorn J. Are corneal cells susceptible to antibody-mediated killing in corneal allograft rejection? Transpl Immunol 2003; 11: 79-89.
61. Ljunggren HG, Ohlen C, Hoglund P, Franksson L, Karre K. The rma-s lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection. Int J Cancer Suppl 1991; 6: 38-44.
62. Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996; 156: 2667-2673.
63. Claerhout I, Kestelyn P, Debacker V, Beele H, Leclercq G. Role of natural killer cells in the rejection process of corneal allografts in rats. Transplantation 2004; 77: 676-82.
64. Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci 1997; 38: 1277-82.
65. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: Role of macrophage migration inhibitory factor in inhibiting nk cell activity and preserving immune privilege. J Immunol 1998; 160: 5693-6.
66. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-20.
67. Bainbridge DR, Ellis SA, Sargent IL. Hla-g suppresses proliferation of cd4(+) t-lymphocytes. J Reprod Immunol 2000; 48: 17-26.
68. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of hla-g in human cornea, an immune-privileged tissue. Hum Immunol 2003; 64: 1039-44.
69. Le Gal FA, Riteau B, Sedlik C, et al. Hla-g-mediated inhibition of antigen-specific cytotoxic t lymphocytes. Int Immunol 1999; 11: 1351-6.
70. Riteau B, Rouas-Freiss N, Menier C, et al. Hla-g2, -g3, and -g4 isoforms expressed as nonmature cell surface glycoproteins inhibit nk and antigen-specific ctl cytolysis. J Immunol 2001; 166: 5018-26.
71. Streilein JW. Immune regulation and the eye: A dangerous compromise. FASEB J 1987; 1: 199-208.
72. Biswas PS, Rouse BT. Early events in hsv keratitis--setting the stage for a blinding disease. Microbes Infect 2005; 7: 799-810.
73. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: Five different paths to herpes stromal keratitis. Immunol Today 1997; 18: 443-9.
74. Kurt-Jones EA, Chan M, Zhou S, et al. Herpes simplex virus 1 interaction with toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A 2004; 101: 1315-20.
75. Mansur DS, Kroon EG, Nogueira ML, et al. Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1. Am J Pathol 2005; 166: 1419-26.
76. Sarangi PP, Kim B, Kurt-Jones E, Rouse BT. Innate recognition network driving herpes simplex virus-induced corneal immunopathology: Role of the toll pathway in early inflammatory events in stromal keratitis. J Virol 2007; 81: 11128-38.
77. Bouley DM, Kanangat S, Rouse BT. The role of the innate immune system in the reconstituted scid mouse model of herpetic stromal keratitis. Clin Immunol Immunopathol 1996; 80: 23-30.
78. Brandt CR, Salkowski CA. Activation of nk cells in mice following corneal infection with herpes simplex virus type-1. Invest Ophthalmol Vis Sci 1992; 33: 113-20.
79. Ghiasi H, Cai S, Perng GC, Nesburn AB, Wechsler SL. The role of natural killer cells in protection of mice against death and corneal scarring following ocular hsv-1 infection. Antiviral Res 2000; 45: 33-45.
80. Oakes JE, Monteiro CA, Cubitt CL, Lausch RN. Induction of interleukin-8 gene expression is associated with herpes simplex virus infection of human corneal keratocytes but not human corneal epithelial cells. J Virol 1993; 67: 4777-84.
81. Tamesis RR, Messmer EM, Rice BA, Dutt JE, Foster CS. The role of natural killer cells in the development of herpes simplex virus type 1 induced stromal keratitis in mice. Eye 1994; 8(Pt 3): 298-306.
82. Doymaz MZ, Rouse BT. Herpetic stromal keratitis: An immunopathologic disease mediated by cd4+ t lymphocytes. Invest Ophthalmol Vis Sci 1992; 33: 2165-73.
83. Doymaz MZ, Rouse BT. Immunopathology of herpes simplex virus infections. Curr Top Microbiol Immunol 1992; 179: 121-36.
84. Hendricks RL, Janowicz M, Tumpey TM. Critical role of corneal langerhans cells in the cd4- but not cd8- mediated immunopathology in herpes simplex virus-1-infected mouse corneas. J Immunol 1992; 148: 2522-9.
85. Niemialtowski MG, Rouse BT. Predominance of th1 cells in ocular tissues during herpetic stromal keratitis. J Immunol 1992; 149: 3035-9.
86. Ksander BR, Hendricks RL. Cell-mediated immune tolerance to hsv-1 antigens associated with reduced susceptibility to hsv-1 corneal lesions. Invest Ophthalmol Vis Sci 1987; 28: 1986-93.
87. Daheshia M, Kuklin N, Kanangat S, Manickan E, Rouse BT. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding il-10. J Immunol 1997; 159: 1945-52.
88. Tumpey TM, Elner VM, Chen SH, Oakes JE, Lausch RN. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. J Immunol 1994; 153: 2258-65.
89. Metcalf JF, Hamilton DS, Reichert RW. Herpetic keratitis in athymic (nude) mice. Infect Immun 1979; 26: 1164-71.
90. Hazlett LD. Bacterial infections of the cornea (pseudomonas aeruginosa). Chem Immunol Allergy 2007; 92: 185-94.
91. Kwon B, Hazlett LD. Association of cd4+ t cell-dependent keratitis with genetic susceptibility to pseudomonas aeruginosa ocular infection. J Immunol 1997; 159: 6283-90.
92. Lighvani S, Huang X, Trivedi PP, Swanborg RH, Hazlett LD. Substance p regulates natural killer cell interferon-gamma production and resistance to pseudomonas aeruginosa infection. Eur J Immunol 2005; 35: 1567-75.
93. Huang X, McClellan SA, Barrett RP, Hazlett LD. Il-18 contributes to host resistance against infection with pseudomonas aeruginosa through induction of ifn-gamma production. J Immunol 2002; 168: 5756-63.
94. Hazlett LD, Qianqian L, Liu J, et al. Nkt cells are critical to initiate an inflammatory response after pseudomonas aeruginosa ocular infection in susceptible mice. J Immunol 2007; 179: 1138-46.
95. Barabino S, Dana MR. Dry eye syndromes. Chem Immunol Allergy 2007; 92: 176-84.
96. Dana MR, Hamrah P. Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye. Adv Exp Med Biol 2002; 506: 729-38.
97. Hemady R, Chu W, Foster CS. Keratoconjunctivitis sicca and corneal ulcers. Cornea 1990; 9: 170-3.
98. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137: 337-42.
99. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci 2007; 48: 2553-60.
100. Jiang G, Ke Y, Sun D, et al. A new model of experimental autoimmune keratoconjunctivitis sicca (kcs) induced in lewis rat by the autoantigen klk1b22. Invest Ophthalmol Vis Sci 2009; 50: 2245-54.
101. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated sjogren's syndrome-like lacrimal keratoconjunctivitis. J Immunol 2006; 176: 3950-7.
102. Stern ME, Gao J, Schwalb TA, et al. Conjunctival t-cell subpopulations in sjogren's and non-sjogren's patients with dry eye. Invest Ophthalmol Vis Sci 2002; 43: 2609-14.
103. El Annan J, Chauhan SK, Ecoiffier T, et al. Characterization of effector t cells in dry eye disease. Invest Ophthalmol Vis Sci 2009; 50: 3802-7.
104. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. The cyclosporin a phase 2 study group. Ophthalmology 2000; 107: 967-74.
105. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of th17 to treg suppression. J Immunol 2009; 182: 1247-52.
106. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. Il-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009; 2: 243-53.
107. Chauhan SK, Dana R. Role of th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol 2009; 2: 375-6.
108. Klyce SD, Beuerman RW, Eds. Structure and function of the cornea, 2nd edcond. Boston, Butterworth-Heinemann, 1997; p. 1109.